New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
07:03 EDTBMYBristol-Myers, CytomX announce collaboration, license agreement
Bristol-Myers Squibb and CytomX Therapeutics announced the companies have signed a worldwide research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform. Under the terms of the agreement, CytomX will grant Bristol-Myers Squibb exclusive worldwide rights to develop and commercialize Probodies for up to four oncology targets including CTLA-4. Bristol-Myers Squibb will have certain additional rights to substitute up to two collaboration targets. Bristol-Myers Squibb will make an upfront payment of $50M to CytomX and provide research funding over the course of the research term. CytomX will also be eligible to receive additional preclinical payments and up to $298M in future development, regulatory and sales milestone payments for each collaboration target, as well as tiered mid-single-digit rising to low-double-digit royalty payments on net sales of each product commercialized by Bristol-Myers Squibb. Closing of the transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
14:42 EDTBMYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
09:35 EDTBMYActive equity options trading on open
Subscribe for More Information
March 30, 2015
11:31 EDTBMYLion Biotechnologies TIL combo data an 'important' positive, says Piper Jaffray
After Lion Biotechnologies (LBIO) announced the report of positive results from a pilot trial of tumor infiltrating lymphocytes, or TIL, in combination with Bristol-Myers' (BMY) Yervoy in patients with metastatic melanoma, Piper Jaffray noted that the success rate for receiving TIL combo treatment was significantly higher than the prior result for TIL monontherapy. Piper said this fact highlights the combo approach may drive significantly broader application of TIL than it initially expected and the firm reiterated its Overweight rating and $21 price target on Lion shares.
March 26, 2015
07:30 EDTBMYDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 24, 2015
08:02 EDTBMYBristol-Myers acquires exclusive license from Novo Nordisk for research program
Subscribe for More Information
March 20, 2015
07:55 EDTBMYAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use